Gedeon Richter and Hetero have partnered to develop and commercialize a proposed generic semaglutide injection, with regulatory submissions planned in the U.S. and Europe in 2027.
Written By: Umesh Hanumante (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Gedeon Richter and Hetero have entered into a global collaboration agreement for the development, registration, and commercialization of a proposed generic Semaglutide Injection, a treatment referencing Novo Nordisk’s widely used GLP-1 receptor agonist Ozempic®.
The partnership aims to expand access to affordable semaglutide therapy by combining the complementary strengths of both companies across product development, manufacturing, regulatory affairs, and commercialization. The agreement reflects growing industry efforts to increase the availability of cost-effective treatment options as demand for GLP-1 medicines continues to rise worldwide.
Meeting Rising Demand for Semaglutide
Semaglutide is one of the most widely prescribed GLP-1 receptor agonists for the treatment of type 2 diabetes. The therapy helps improve blood glucose control and has also demonstrated benefits in weight management, contributing to strong global demand across healthcare markets.
The rapid adoption of GLP-1 therapies has created significant interest among healthcare providers, payers, and patients seeking effective treatment options for chronic metabolic diseases. As healthcare systems face increasing pressure from the growing prevalence of type 2 diabetes and obesity, improving access to affordable therapies has become an important priority.
Through the collaboration, Hetero and Richter aim to leverage their respective market strengths to support broad international access to semaglutide treatment. According to the companies, Hetero brings extensive capabilities in the United States and emerging markets, while Richter contributes an established commercial presence across Europe and Central Asia.
Regulatory Submissions Planned for 2027
Hetero has already invested in technology development and registration batch manufacturing to support the semaglutide program. The companies plan to submit regulatory applications for the proposed generic semaglutide injection in both the United States and Europe during 2027.
The agreement also includes the potential for future European manufacturing by Richter, supporting long-term supply reliability and commercialization efforts across key markets.
While the collaboration marks an important development milestone, future commercialization timelines will remain subject to regulatory review processes as well as intellectual property and market exclusivity considerations that may vary across jurisdictions.
Clinical Implications
Dr. Bence Kovács, Global Head of General Medicines at Richter, said the partnership demonstrates a shared commitment to providing patients with access to high-quality and affordable treatment options for diabetes and other cardiometabolic diseases.
Dr. Vamsi Krishna Bandi, Managing Director of Hetero Labs, stated that the collaboration brings together the complementary expertise of both organizations and has the potential to expand patient access to semaglutide therapy on a global scale.
Market Implications
The agreement comes as the global market for GLP-1 receptor agonists continues to expand rapidly, driven by increasing demand for innovative therapies that address both glycemic control and broader cardiometabolic health needs.
Industry observers expect greater competition within the semaglutide market over the coming years as companies pursue development opportunities in anticipation of future market openings. Partnerships such as the one between Richter and Hetero are expected to play an important role in supporting affordability, strengthening supply chains, and improving patient access to essential therapies.
If successfully developed and approved, the proposed generic semaglutide injection could provide a lower-cost treatment alternative for patients living with type 2 diabetes while helping expand access to one of the pharmaceutical industry’s most important therapeutic classes.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.
